A promising therapeutic combination for metastatic prostate cancer: Chloroquine as autophagy inhibitor and palladium(II) barbiturate complex
dc.contributor.author | Akar, Remzi Okan | |
dc.contributor.author | Aztopal, Nazlıhan | |
dc.contributor.author | Cevatemre, Buse | |
dc.contributor.buuauthor | Erkısa, Merve | |
dc.contributor.buuauthor | Aydınlık, Şeyma | |
dc.contributor.buuauthor | Cevatemre, Buse | |
dc.contributor.buuauthor | Çelikler, Serap | |
dc.contributor.buuauthor | Yılmaz, Veysel Turan | |
dc.contributor.buuauthor | Arı, Ferda | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Kimya Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-3127-742X | tr_TR |
dc.contributor.orcid | 0000-0001-5238-2432 | tr_TR |
dc.contributor.orcid | 0000-0002-4177-3478 | tr_TR |
dc.contributor.orcid | 0000-0002-2849-3332 | tr_TR |
dc.contributor.orcid | 0000-0002-6729-7908 | tr_TR |
dc.contributor.researcherid | AAM-1001-2020 | |
dc.contributor.researcherid | ABI-2909-2020 | |
dc.contributor.researcherid | AAH-2767-2021 | |
dc.contributor.researcherid | L-7238-2018 | |
dc.contributor.researcherid | AAG-7012-2021 | |
dc.contributor.scopusid | 57126208900 | |
dc.contributor.scopusid | 57190280044 | |
dc.contributor.scopusid | 8234554800 | |
dc.contributor.scopusid | 56441123900 | |
dc.contributor.scopusid | 24376085300 | |
dc.date.accessioned | 2024-02-23T11:01:58Z | |
dc.date.available | 2024-02-23T11:01:58Z | |
dc.date.issued | 2020-08 | |
dc.description.abstract | Autophagy is a catabolic process for cells that can provide energy sources and allows cancer cells to evade cell death. Therefore, studies on the combination of autophagy inhibitors with drugs are increasing as a new treatment modality in cancer. Previously, we reported the anti-tumor activity of a Palladium (Pd)(II) complex against different types of cancer in vitro and in vivo. Chloroquine (CQ), the worldwide used anti-malarial drug, has recently been focused as a chemosensitizer in cancer treatment. The aim of this study was to investigate the efficacy of a combined treatment of these agents that work through different mechanisms to provide an effective treatment modality for metastatic prostate cancer that is certainly fatal. Metastatic prostate cancer cell lines (PC-3 and LNCaP) were treated with Pd (II) complex, CQ, and their combination. The combination enhanced apoptosis by increasing phosphatidylserine translocation and pro-apoptotic proteins. Apoptosis was confirmed by the use of apoptosis inhibitor. The formation of acidic vesicular organelles (AVOs) was observed by acridine orange staining in fluorescence microscopy. The Pd (II) complex increased AVOs formation in prostate cancer cells and CQ-pretreatment has potentiated this effect. Importantly, treatment with CQ suppressed the pro-survival function of autophagy, which might have contributed to enhanced cytotoxicity. In addition, PI3K/AKT/mTOR-related protein expressions were altered after the combination of treatments. Our results suggest that combination treatment enhances apoptotic cell death possibly via the inhibition of autophagy, and may therefore be regarded as a novel and better approach for the treatment of metastatic prostate cancer. | en_US |
dc.identifier.citation | Erkısa, M. vd. (2020). "A promising therapeutic combination for metastatic prostate cancer: Chloroquine as autophagy inhibitor and palladium(II) barbiturate complex". Biochimie, 175, 159-172. | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.biochi.2020.05.010 | |
dc.identifier.endpage | 172 | tr_TR |
dc.identifier.issn | 0300-9084 | |
dc.identifier.issn | 1638-6183 | |
dc.identifier.pubmed | 32497551 | tr_TR |
dc.identifier.scopus | 2-s2.0-85086773048 | tr_TR |
dc.identifier.startpage | 159 | tr_TR |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0300908420301176 | |
dc.identifier.uri | https://hdl.handle.net/11452/39934 | |
dc.identifier.volume | 175 | tr_TR |
dc.identifier.wos | 000579382300017 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.bap | OUAP(T)-2015/19 | tr_TR |
dc.relation.collaboration | Yurt içi | |
dc.relation.collaboration | Sanayi | |
dc.relation.journal | Biochimie | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Autophagy | en_US |
dc.subject | DNA damage | en_US |
dc.subject | Pro-survival | en_US |
dc.subject | Enhanced cytotoxic activity | en_US |
dc.subject | Cell apoptosis | en_US |
dc.subject | In-vitro | en_US |
dc.subject | Induction | en_US |
dc.subject | Resistance | en_US |
dc.subject | Pathways | en_US |
dc.subject | Fusionassay | en_US |
dc.subject | Growth | en_US |
dc.subject | Acid | en_US |
dc.subject | Biochemistry & molecular biology | en_US |
dc.subject.emtree | Acridine orange | en_US |
dc.subject.emtree | Apoptosis inhibitor | en_US |
dc.subject.emtree | Autophagy related protein | en_US |
dc.subject.emtree | Caspase 3 | en_US |
dc.subject.emtree | Chloroquine | en_US |
dc.subject.emtree | Cyclic AMP responsive element binding protein | en_US |
dc.subject.emtree | Dansylcadaverine | en_US |
dc.subject.emtree | Lc3 ii protein | en_US |
dc.subject.emtree | Mammalian target of rapamycin | en_US |
dc.subject.emtree | Palladium complex | en_US |
dc.subject.emtree | Phosphatidylinositol 3 kinase | en_US |
dc.subject.emtree | Phosphatidylserine | en_US |
dc.subject.emtree | Protein kinase B | en_US |
dc.subject.emtree | STAT5 protein | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Barbituric acid | en_US |
dc.subject.emtree | Barbituric acid derivative | en_US |
dc.subject.emtree | Chloroquine | en_US |
dc.subject.emtree | Coordination compound | en_US |
dc.subject.emtree | Palladium | en_US |
dc.subject.emtree | Akt signaling; apoptosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Autophagy (cellular) | en_US |
dc.subject.emtree | Cell membrane depolarization | en_US |
dc.subject.emtree | Cell organelle | en_US |
dc.subject.emtree | Cell survival | en_US |
dc.subject.emtree | Cell viability | en_US |
dc.subject.emtree | Combination drug therapy | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | DNA damage | en_US |
dc.subject.emtree | Drug cytotoxicity | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Flow cytometry | en_US |
dc.subject.emtree | Fuorescence microscopy | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | IC50 | en_US |
dc.subject.emtree | LNCaP cell line | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Metastasis | en_US |
dc.subject.emtree | Mitochondrial membrane potential | en_US |
dc.subject.emtree | MTT assay | en_US |
dc.subject.emtree | Oxidative stress | en_US |
dc.subject.emtree | PC-3 [Human prostate carcinoma] cell line | en_US |
dc.subject.emtree | Proapoptotic activity | en_US |
dc.subject.emtree | Prostate cancer | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Protein phosphorylation | en_US |
dc.subject.emtree | Western blotting | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Metastasis | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Prostate tumor | en_US |
dc.subject.mesh | Antineoplastic combined chemotherapy protocols | en_US |
dc.subject.mesh | Apoptosis | en_US |
dc.subject.mesh | Barbiturates | en_US |
dc.subject.mesh | Chloroquine | en_US |
dc.subject.mesh | Coordination complexes | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Neoplasm metastasis | en_US |
dc.subject.mesh | Palladium | en_US |
dc.subject.mesh | PC-3 cells | en_US |
dc.subject.mesh | Prostatic neoplasms | en_US |
dc.subject.scopus | Beclin 1; Chloroquine; Cancer Cell | en_US |
dc.subject.wos | Biochemistry & molecular biology | en_US |
dc.title | A promising therapeutic combination for metastatic prostate cancer: Chloroquine as autophagy inhibitor and palladium(II) barbiturate complex | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: